
Europe In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
Description
Europe In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
Europe In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
Europe In-Vitro Colorectal Cancer Screening Tests Market Outlook
The global in-vitro colorectal cancer screening tests market size was valued at USD 920.4 million in 2023, with Europe holding a significant market share. The market is driven by the rising prevalence of colorectal cancer across the region. It is expected to grow at a CAGR of 5.90% during the forecast period of 2024-2032, with the values likely to attain USD 1492.8 million by 2032.
Key Takeaways
- According to the World Health Organization, the burden of colorectal cancer is expected to rise to about 3.2 million new cases per year and nearly 1.6 million deaths per year by 2024. The highest mortality rates have been witnessed in Eastern Europe.
- Rising research activities are creating opportunities for Europe in-vitro colorectal cancer screening tests market growth. In February 2024, researchers at the Netherlands Cancer Institute, Amsterdam UMC, and Erasmus MC developed a new test called multitargetFIT-test (mtFIT), that measures hemoglobin with two additional proteins during the detection of pre-cursors of colorectal cancer.
- The market is expected to be driven by clinical-stage diagnostics companies understanding the need to explore their screening technologies to detect colorectal cancer, brain cancer, and lung cancer. Dxcover Limited announced initiating three clinical trials to measure the efficacy of their liquid biopsy technology in the mentioned conditions.
Colorectal cancer is the third most common cancer across the globe. It claims nearly 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide. According to the World Health Organization, in 2020, more than 1.9 million new cases of colorectal cancer were recorded globally. Europe, Australia, and New Zealand experienced the highest incidence rates, and the mortality rates were highest in Eastern Europe. It is expected that the burden of colorectal cancer will increase to 3.2 million new cases per year (an increase of 63%) by 2040, and 1.6 million deaths per year (an increase of 73%).
Europe in-vitro colorectal cancer screening tests market share is expected to be elevate with increasing strategic moves of market players. Considering the urgency of diagnosing colorectal cancer in its early stages with accuracy, there have been dedicated efforts to develop effective products. On January 9, 2024, a clinical-stage diagnostics company Dxcover Limited, pioneering in multi-omic spectral analysis (MOSA) for the early detection of multiple cancers, announced the initiation of three pivotal clinical trials, measuring the efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal, and lung cancer. Their CREATE2 trial is focused on evaluating the diagnostic accuracy for colorectal cancer and high-risk adenoma in patients who have been going through colonoscopy. With colorectal cancer already difficult to diagnose in early detection screenings, diagnosis at these stages will enable positive patient outcomes.
Europe in-vitro colorectal cancer screening tests market growth is anticipated to be positively impacted by the researchers innovating new testing methods for the detection of precursors of colorectal cancer. For instance, in February 2024, researchers at the Netherlands Cancer Institute, Amsterdam UMC, and Erasmus MC developed a new test, titled multitargetFIT-test (mtFIT). With the existing FIT test, the patient’s stool is analysed for hemoglobin, however mtFIT measures hemoglobin and two additional proteins. mtFIT is targeted to detect cancer precursors more effectively. Notable outcomes have also been registered in a large prospective study, in which mtFIT effectively detected cancer precursors in comparison to the current FIT. Based on the diagnostic test guidelines in Europe, the next step is to produce the mtFIT test on a larger industrial scale. This is because the test can be included in existing FIT-based screening programs, as the screening logistics requirements are similar. To facilitate the availability of the test for CRC screening participants in the Netherlands and other places, a company called CRCbioscreen has also been established.
Europe In-Vitro Colorectal Cancer Screening Tests Market Segmentation
Market Breakup by Testing Type
- Fecal Occult Blood Tests
- Biomarker Tests
- CRC DNA Screening Tests
- Flexible Sigmoidoscopy
- Others
- Colonoscopy
- Proctoscopy
- CT scan
- Ultrasound
- MRI
- PET Scan
- Hospitals
- Clinics
- Diagnostics Laboratories
- United Kingdom
- Germany
- France
- Italy
- Others
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Epigenomics AG
- NOVIGENIX SA
- Merck KGaA
- Abbott
- Siemens Healthineers AG
- Sysmex Corporation
- Qiagen NV
- F. Hoffmann-La Roche Ltd
- Eiken Chemical Co., Ltd.
- Beckman Coulter, Inc.
FAQs
- What was the Europe in-vitro colorectal cancer screening tests market value in 2023?
- What are the major factors aiding the Europe in-vitro colorectal cancer screening tests market demand?
- What are the major Europe in-vitro colorectal cancer screening tests market trends?
- What is the market segmentation based on testing type?
- What is the market breakup by imaging type?
- What are the major end users of the market?
- What is the market segmentation by countries?
- Who are the key players involved in the European in-vitro colorectal cancer screening tests market?
Meta description
The Europe in-vitro colorectal cancer screening tests market is poised for growth, driven by the expansion of the global market, which was valued at USD 920.4 million in 2023 and is projected to grow at a CAGR of 5.53% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Europe In-vitro Colorectal Cancer Screening Tests Market Overview
- 3.1 Europe In-vitro Colorectal Cancer Screening Tests Market Historical Value (2017-2023)
- 3.2 Europe In-vitro Colorectal Cancer Screening Tests Market Forecast Value (2024-2032)
- 4 Europe In-vitro Colorectal Cancer Screening Tests Market Landscape*
- 4.1 Europe In-vitro Colorectal Cancer Screening Tests: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Europe In-vitro Colorectal Cancer Screening Tests: Product Landscape
- 4.2.1 Analysis by Test Type
- 4.2.2 Analysis by Imaging Type
- 5 Europe In-vitro Colorectal Cancer Screening Tests Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Europe In-vitro Colorectal Cancer Screening Tests Market Segmentation (2017-2032)
- 6.1 Europe In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 6.1.1 Market Overview
- 6.1.2 Fecal Occult Blood Tests
- 6.1.3 Biomarker Tests
- 6.1.4 CRC DNA Screening Tests
- 6.1.5 Flexible Sigmoidoscopy
- 6.1.6 Others
- 6.2 Europe In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 6.2.1 Market Overview
- 6.2.2 Colonoscopy
- 6.2.3 Proctoscopy
- 6.2.4 CT scan
- 6.2.5 Ultrasound
- 6.2.6 MRI
- 6.2.7 PET Scan
- 6.3 Europe In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 6.3.1 Market Overview
- 6.3.2 Hospitals
- 6.3.3 Clinics
- 6.3.4 Diagnostics Laboratories
- 6.3.5 Others
- 6.4 Europe In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
- 6.4.1 Market Overview
- 6.4.2 United Kingdom
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 Italy
- 6.4.6 Others
- 7 United Kingdom In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 7.1 United Kingdom In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 7.1.1 Market Overview
- 7.1.2 Fecal Occult Blood Tests
- 7.1.3 Biomarker Tests
- 7.1.4 CRC DNA Screening Tests
- 7.1.5 Flexible Sigmoidoscopy
- 7.1.6 Others
- 7.2 United Kingdom In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 7.2.1 Market Overview
- 7.2.2 Colonoscopy
- 7.2.3 Proctoscopy
- 7.2.4 CT Scan
- 7.2.5 Ultrasound
- 7.2.6 MRI
- 7.2.7 PET Scan
- 7.3 United Kingdom In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 7.3.1 Market Overview
- 7.3.2 Hospitals
- 7.3.3 Clinics
- 7.3.4 Diagnostics Laboratories
- 7.3.5 Others
- 8 Germany In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 8.1 Germany In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 8.1.1 Market Overview
- 8.1.2 Fecal Occult Blood Tests
- 8.1.3 Biomarker Tests
- 8.1.4 CRC DNA Screening Tests
- 8.1.5 Flexible Sigmoidoscopy
- 8.1.6 Others
- 8.2 Germany In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 8.2.1 Market Overview
- 8.2.2 Colonoscopy
- 8.2.3 Proctoscopy
- 8.2.4 CT Scan
- 8.2.5 Ultrasound
- 8.2.6 MRI
- 8.2.7 PET Scan
- 8.3 Germany In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 8.3.1 Market Overview
- 8.3.2 Hospitals
- 8.3.3 Clinics
- 8.3.4 Diagnostics Laboratories
- 8.3.5 Others
- 9 France In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 9.1 France In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 9.1.1 Market Overview
- 9.1.2 Fecal Occult Blood Tests
- 9.1.3 Biomarker Tests
- 9.1.4 CRC DNA Screening Tests
- 9.1.5 Flexible Sigmoidoscopy
- 9.1.6 Others
- 9.2 France In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 9.2.1 Market Overview
- 9.2.2 Colonoscopy
- 9.2.3 Proctoscopy
- 9.2.4 CT Scan
- 9.2.5 Ultrasound
- 9.2.6 MRI
- 9.2.7 PET Scan
- 9.3 France In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 9.3.1 Market Overview
- 9.3.2 Hospitals
- 9.3.3 Clinics
- 9.3.4 Diagnostics Laboratories
- 9.3.5 Others
- 10 Italy In-vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 10.1 Italy In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Testing Type
- 10.1.1 Market Overview
- 10.1.2 Fecal Occult Blood Tests
- 10.1.3 Biomarker Tests
- 10.1.4 CRC DNA Screening Tests
- 10.1.5 Flexible Sigmoidoscopy
- 10.1.6 Others
- 10.2 Italy In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by Imaging Type
- 10.2.1 Market Overview
- 10.2.2 Colonoscopy
- 10.2.3 Proctoscopy
- 10.2.4 CT Scan
- 10.2.5 Ultrasound
- 10.2.6 MRI
- 10.2.7 PET Scan
- 10.3 Italy In-vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 10.3.1 Market Overview
- 10.3.2 Hospitals
- 10.3.3 Clinics
- 10.3.4 Diagnostics Laboratories
- 10.3.5 Others
- 11 Regulatory Framework
- 12 Funding and Investment Analysis
- 12.1 Analysis by Funding Instances
- 12.2 Analysis by Type of Funding
- 12.3 Analysis by Funding Amount
- 12.4 Analysis by Leading Players
- 12.5 Analysis by Leading Investors
- 12.6 Analysis by Geography
- 13 Partnership and Collaborations Analysis
- 13.1 Analysis by Partnership Instances
- 13.2 Analysis by Type of Partnership
- 13.3 Analysis by Leading Players
- 13.4 Analysis by Geography
- 14 Supplier Landscape
- 14.1 Market Share by Top 5 Companies
- 14.2 Epigenomics AG
- 14.2.1 Financial Analysis
- 14.2.2 Product Portfolio
- 14.2.3 Demographic Reach and Achievements
- 14.2.4 Mergers and Acquisitions
- 14.2.5 Certifications
- 14.3 NOVIGENIX SA
- 14.3.1 Financial Analysis
- 14.3.2 Product Portfolio
- 14.3.3 Demographic Reach and Achievements
- 14.3.4 Mergers and Acquisitions
- 14.3.5 Certifications
- 14.4 Merck KGaA
- 14.4.1 Financial Analysis
- 14.4.2 Product Portfolio
- 14.4.3 Demographic Reach and Achievements
- 14.4.4 Mergers and Acquisitions
- 14.4.5 Certifications
- 14.5 Abbott
- 14.5.1 Financial Analysis
- 14.5.2 Product Portfolio
- 14.5.3 Demographic Reach and Achievements
- 14.5.4 Mergers and Acquisitions
- 14.5.5 Certifications
- 14.6 Siemens Healthineers AG
- 14.6.1 Financial Analysis
- 14.6.2 Product Portfolio
- 14.6.3 Demographic Reach and Achievements
- 14.6.4 Mergers and Acquisitions
- 14.6.5 Certifications
- 14.7 Sysmex Corporation
- 14.7.1 Financial Analysis
- 14.7.2 Product Portfolio
- 14.7.3 Demographic Reach and Achievements
- 14.7.4 Mergers and Acquisitions
- 14.7.5 Certifications
- 14.8 Qiagen NV
- 14.8.1 Financial Analysis
- 14.8.2 Product Portfolio
- 14.8.3 Demographic Reach and Achievements
- 14.8.4 Mergers and Acquisitions
- 14.8.5 Certifications
- 14.9 F. Hoffmann-La Roche Ltd
- 14.9.1 Financial Analysis
- 14.9.2 Product Portfolio
- 14.9.3 Demographic Reach and Achievements
- 14.9.4 Mergers and Acquisitions
- 14.9.5 Certifications
- 14.10 Eiken Chemical Co., Ltd.
- 14.10.1 Financial Analysis
- 14.10.2 Product Portfolio
- 14.10.3 Demographic
- 14.10.4 Mergers and Acquisitions
- 14.10.5 Certifications
- 14.11 Beckman Coulter, Inc.
- 14.11.1 Financial Analysis
- 14.11.2 Product Portfolio
- 14.11.3 Demographic Reach and Achievements
- 14.11.4 Mergers and Acquisitions
- 14.11.5 Certifications
- 15 Europe In-vitro Colorectal Cancer Screening Tests Market – Distribution Model (Additional Insight)
- 15.1 Overview
- 15.2 Potential Distributors
- 15.3 Key Parameters for Distribution Partner Assessment
- 16 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 17 Company Competitiveness Analysis (Additional Insight)
- 17.1 Very Small Companies
- 17.2 Small Companies
- 17.3 Mid-Sized Companies
- 17.4 Large Companies
- 17.5 Very Large Companies
- 18 Payment Methods (Additional Insight)
- 18.1 Government Funded
- 18.2 Private Insurance
- 18.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.